23067-79-0

Basic information

• Product Name: 8-tert-butylchroman-4-one
• Synonyms: 8-tert-butylchroman-4-one;8-(tert-butyl)-2,3-dihydro-4H-1-benzopyran-4-one
• CAS NO: 23067-79-0
• Molecular Formula: C13H16O2
• Molecular Weight: 204.26494
• Mol File: 23067-79-0.mol

Chemical Properties

• Boiling Point: 323.935°C at 760 mmHg
• Flash Point: 141.85°C
• Appearance: /
• Density: 1.072
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.527
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 8-tert-butylchroman-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 8-tert-butylchroman-4-one(23067-79-0)
• EPA Substance Registry System: 8-tert-butylchroman-4-one(23067-79-0)

Safety Data

• Hazardous Substances Data: 23067-79-0(Hazardous Substances Data)

Usage

Uses

Used in Food Industry:
8-Tert-butylchroman-4-one is used as an antioxidant for extending the shelf life of food products. Its ability to scavenge free radicals and protect against oxidative stress helps maintain the freshness and quality of food items.
Used in Cosmetic Industry:
8-Tert-butylchroman-4-one is used as an active ingredient in anti-aging and skincare products. Its antioxidant properties help protect the skin from environmental stressors and promote a youthful appearance.
Used in Pharmaceutical Industry:
8-Tert-butylchroman-4-one is studied for its potential therapeutic uses in the treatment of various diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions. Its antioxidant properties may contribute to the prevention and management of these health issues.

InChI:InChI=1/C13H16O2/c1-13(2,3)10-6-4-5-9-11(14)7-8-15-12(9)10/h4-6H,7-8H2,1-3H3

Upstream product

• 88-18-6 2-tert-Butylphenol 
• 55619-88-0 1-(tert-butyl)-2-(prop-2-yn-1-yloxy)benzene 
• 890839-78-8 1-(tert-Butyl)-2-((3-chloroprop-2-yn-1-yl)oxy)benzene 

Downstream Products

• 1221444-51-4 (R)-8-tert-butylchroman-4-amine 
• 1228553-77-2 C₁₃H₁₉NO 

Relevant articles and documents

Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases

The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administrating these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.

TRPV1 ANTAGONISTS

Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 ANTAGONISTS

Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF

The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

Prodrugs of compounds that inhibit TRPV1 receptor

Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladd

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.